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Abstract. Distinct  epidemiological  characteristics  have  been  described  in  Acute 
Leukemia (APL). Populations from Latin America have a higher incidence of APL and in some 
geographic areas a distinct distribution of the PML
main differences in APL epidemilogy in Latin America a
Introduction. Geographical  variations  in  frequency 
and  clinical  characteristics  of  hematological 
malignancies  in  patients  from  Europe/US 
from Latin America have been described in lymphoid 
malignancies,
1-4 and    to  a  lesser  extend  in  myeloid 
neoplasms.
5-8 Acute Promyelocytic Leukemia (APL) is 
a distinct type of myeloid leukemia characterized by its 
invariable association with chromosomal translocations 
involving the Retinoid Acid Receptor 
chromosome  17.  The  breakpoints  in 
clustered in relatively short span in intron 3. Likewise, 
the breakpoints in the Promyelocytic Leukemia
gene,  the  main  partner  of  RARA in  APL
rearrangements, are clustered in three regions: one in 
exon 3 originating the short form type of 
fusion gene, or bcr3, and two in exon 6: the long form, 
or bcr1 and the variable form, or bcr2.
9
that the PML-RARA is detected in more than 98% of 
patients with APL, the disease is a paradigm of acute 
; Open Journal System 
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Distinct  epidemiological  characteristics  have  been  described  in  Acute 
Leukemia (APL). Populations from Latin America have a higher incidence of APL and in some 
geographic areas a distinct distribution of the PML-RARA isoforms is present. Here, we review the 
main differences in APL epidemilogy in Latin America as well as treatment outcomes.
Geographical  variations  in  frequency 
and  clinical  characteristics  of  hematological 
malignancies  in  patients  from  Europe/US  and  those 
from Latin America have been described in lymphoid 
and    to  a  lesser  extend  in  myeloid 
Acute Promyelocytic Leukemia (APL) is 
a distinct type of myeloid leukemia characterized by its 
invariable association with chromosomal translocations 
 (RARA) gene in 
chromosome  17.  The  breakpoints  in  RARA  are 
in relatively short span in intron 3. Likewise, 
Promyelocytic Leukemia (PML) 
in  APL-associated 
rearrangements, are clustered in three regions: one in 
exon 3 originating the short form type of PML-RARA
fusion gene, or bcr3, and two in exon 6: the long form, 
9 Due to the fact 
is detected in more than 98% of 
patients with APL, the disease is a paradigm of acute 
myeloid  leukemia  (AML)  associated  with 
chromosomal translocations. In addition, APL is also 
distinct from other AML subtypes for its response to 
the  all  trans retinoic  acid  (ATRA),  which  induces 
terminal  granulocytic  differentiation  of  the  blasts. 
Consequently,  the  combined  use  of  ATR
anthracyclines  has  become  the  mainstay  of  APL 
therapy  and  several  trials  reported  cure  rates  above 
80%.
10
Despite the great improving in APL treatment, very 
few is known on the outcome of APL patients and their 
characteristics in developing countries, mostly due to 
absence of well structured networks that could permit 
sharing  experiences  and  accrual  of  large  n
patients.  Only  recently,  the  International  Members 
Committee  of  the  American  Society  of  Hematology 
proposed the creation of a group that would create the 
necessary  integration  for  collaboration  in  developing 
countries in an effort named Internatio
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Distinct  epidemiological  characteristics  have  been  described  in  Acute  Promielocytic 
Leukemia (APL). Populations from Latin America have a higher incidence of APL and in some 
RARA isoforms is present. Here, we review the 
s well as treatment outcomes.
myeloid  leukemia  (AML)  associated  with  recurrent 
chromosomal translocations. In addition, APL is also 
distinct from other AML subtypes for its response to 
retinoic  acid  (ATRA),  which  induces 
terminal  granulocytic  differentiation  of  the  blasts. 
Consequently,  the  combined  use  of  ATRA  and 
anthracyclines  has  become  the  mainstay  of  APL 
therapy  and  several  trials  reported  cure  rates  above 
Despite the great improving in APL treatment, very 
few is known on the outcome of APL patients and their 
characteristics in developing countries, mostly due to 
absence of well structured networks that could permit 
sharing  experiences  and  accrual  of  large  number  of 
patients.  Only  recently,  the  International  Members 
Committee  of  the  American  Society  of  Hematology 
proposed the creation of a group that would create the 
necessary  integration  for  collaboration  in  developing 
countries in an effort named International Consortium Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
on Acute Promyelocytic Leukemia.
APL  Characteristics  in  Latin  America.  The  data 
available on specific characteristics of APL patients on 
Latin  America  are  from  reports  by  single  or  few 
centers.  Population  based  information  is  unavailable, 
due to inaccurate registries. Douer D et al
11 were the 
first to report specific features of APL in patients with 
‘latin’  and  ‘non  latin’  ancestry.  Data  from  a  single 
institution  as  well  as  a  population-based  study 
suggested  that  the  Latino  population  had  a  higher 
proportion of APL among all AML diagnosis, which 
reached  37.5%  against  6.4%  in  the  non-Latino 
population. Nevertheless, Latino is not an ethnicity and 
is very difficult to define what is the characteristic of 
such  population.  The  authors  define  as  those 
originating  in  Latin  America,  but  the  genetic 
background of people from different areas of this vast 
region is  very different. Spanish, Portuguese, Italian, 
African and others are present at different proportions 
with the native Americans which, by themselves vary 
as  much  as  Mayan,  Aztecs  and  the  different 
Amerindians tribes from Brazil. Ruiz-Arguelles, GJ
12
suggested  that  Latino  should  be  considered  as  those 
speaking languages derived from Latin, but this also 
implies  in  very  imprecise  characterization,  putting 
together  populations  so  different  as  French,  Italians, 
Romanians, Brazilians and Uruguayans among others.
No  matter  definitions,  there  is  sufficient  data  on 
medical  literature  to  support  the  fact  that  distinct 
populations have different incidences of APL. We have 
reported that APL represents 28.2% of all AML cases 
in centers in Brazil, a number that is very similar to the 
reported by Melo, R et al (28%).
13 This is ratified by 
information  from  Mexico  (20%), 
12 Venezuela 
(27.8%)
14 and Peru (22%).
15 This is also true among 
children, despite the fact that APL is less common in 
this age group.
16 The reason for this high incidence is 
to be explored. One may argue that in countries with 
difficult access to health support the young would have 
priority  and,  as  APL  has  higher  incidence  in  young 
adults,  it  would  falsify  the  true incidence  of  other 
AML. However, a study conducted in Spain have also 
demonstrated a variable incidence of APL in different 
regions of the country.
17 While the Northern region had 
relative  incidence  of  12.6%,  in  the  Southern  it  was 
21.6%. Another study from Spain has reported 23% of 
incidence  of  APL.
18 Studies  from  Italy  suggest  an 
incidence  of  11.5%,  ranging  from  27.7%  in  patients 
between 15 and 24 age years and 2.7% in older than 75 
years.
19 Since well controlled epidemiological studies 
carried  out  in  UK
20 and  Scandinavian
21 countries 
indicated that APL represented about 10% of all AML 
cases,  one  may  argue  that  the  incidence  is  lower  in 
Northern Europe compared to Mediterranean countries, 
and  in  consequently  in  their  former  colonies  in 
America.  
Apart  from  the  issue  of  incidence,  some 
peculiarities regarding the clinical features have been 
described in patients from Latin America.
22 In a survey 
evolving  12  Brazilian  institutions  that  treat 
hematologic malignancies we observed that the mean 
age  of  diagnosis  (36  years)  and  gender  distribution 
(male 45.8% and female 54.8%) did not differ from the 
observed  in  literature.
6 Furthermore,  we  noticed  that 
there  was  a  high  incidence  of  the  high  relapse  risk 
group  as  defined  by  the  PETHEMA  and  GIMEMA 
groups.
23 In our  report,  36.9%  of  the  patients  had  a 
white  blood  cell  (WBC)  counts  above  10,000  /  L 
contrasting with 22.6% of the combined Spanish and 
Italian experiences (p<0.001). This excess of high-risk 
patients may be secondary to difficult access to health 
assistance.  It  is  worth  noting  that  we  did  not  detect 
differences in the distribution among PML breakpoint 
clustering  regions  (bcrs),  with  54.3%  of  patients 
harboring the bcr1 isoform.
6 This is relevant because 
bcr3  cases  have  been  associated  with  higher  WBC
counts.
24 Douer D et al reported a proportion of 75% of 
the bcr1 isoform of PML-RARA higher than the usual 
50-55% reported in  clinical trials.
23,25 Further data is 
not  homogeneous.  A population of Mexican Mestizo 
APL patients showed 63% of bcr1 and in a population 
from  the  Northeast  of  Brazil  there  were  68.8%  of 
bcr1/bcr2. This relative incidence is very similar to the 
reported in China (67%)
26 and a combined Uruguayan 
and Argentinean report (62%).
27
APL Treatment in Latin America. The majority of 
centers  in  Latin  America  adopt  protocols  based  on 
ATRA plus anthracyclines, similar to those reported by 
the  Italian  GIMEMA  or  the  Spanish  PETHEMA 
groups.  However,  a  major  concern  is  the  cost  of 
treatment.  To  supplant  the  high  cost  of  idarubicin, 
many hospitals in Brazil adapt the protocol to another 
anthracycline such as daunorubicin
28 or mitoxantrone.
29
In our 12 center survey,
6 we observed that three centers 
used distinct protocols not based on antracyclines and 
ATRA. Two used ATRA alone until remission and one 
of them used to consolidate with front line autologous 
bone  marrow  transplantation.  A  third  one  used  a 
multiple drug protocol in induction. 
Results  from  institutions  that  use  AIDA  similar 
regimens  are not  remarkable.  In  a  single  pediatric 
institution report, da Costa Moraes et al described that, 
among fourteen patients with APL diagnosis only five 
were discharged for follow-up.
28 Pagnano et al reported 
similar results.
29 In their report, in a seven-year period, 
out of 19 APL patients only eleven finished induction 
and eight finished the third consolidation cycle with a 
disease-free survival estimated of 82% at 120 months. Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
This report raises an important issue in APL patients’ 
treatment. Death during chemotherapy was higher than 
in developed countries and the main causes of death 
were bleeding, infection and differentiation syndrome.
These  results  were  corroborated  by  our  larger 
survey analysing 134 patients treated with antracycline 
plus ATRA based therapy.
6 Induction mortality was as 
high as 32.1% and bleeding was the cause of death in 
60.5%.  of  the  cases.  Even  during  consolidation  we 
observed a mortality rate of 10.5%, and mortality was 
mainly due to bleeding (21.4%), infection (28.6%) or 
their  association  (14.3%).  The  cumulative  mortality 
was 44.7%.
The high incidence of high risk patients reported in 
the  series  from Brazil  as  well  as the  large mortality 
during treatment suggest that two main points should 
be  addressed:  expedite  diagnosis  and  better  support 
during treatment. This could be achieved with a high 
motivational  effort  and  also  with  a  network  of 
specialists that could exchange experiences and create 
a  well  established  protocol  and  unified  support 
treatment guidelines. Previous efforts have shown that 
collaboration  and  educational  programs  can  interfere 
with  the  outcome  of  cancer  patients,  specifically  in 
children.
30-32
APL  is  a  very  good  candidate  for  collaboration. 
Treatment protocols are not complex and costs are not 
high.  Furthermore,  a  high  suspicious  diagnosis  is 
possible  due  to  its  characteristic  morphology  and 
bleeding tendency. The confirmatory diagnosis can be 
made  in  a  few  hours  with  an  immunocytochemistry 
technique
33 that  requires  only  a  fluorescence 
microscope  and  minimal  training.
34 Finally,  the 
molecular  characterization  can  be  made  in  central 
laboratory with higher level of complexity.
Confronting  the  situation  of  APL  in  developing 
countries  and  the  potential  results  that  could  be 
achieved the American Society of Hematology through 
its  International  Members  Committee  proposed  a 
collaboration  effort  evolving  developing  countries 
named  International  Consortium  on  Acute 
Promyelocytic Leukemia (IC APL). Specialists in APL 
field from innumerous countries integrate the IC APL 
and  nowadays  the  group  runs  a  protocol  in  Brazil, 
Mexico, Uruguay and Chile. The protocol is similar to 
the  PETHEMA  2005,
35 but  changing  idarubicin  to 
daunorubicin.  We  recently  reported  preliminary  data 
from  97  patients  included  in  the  IC  APL  2006 
protocol.
36 There  was a  remarkable  improvement  in 
survival that reached 75% in one year and the disease-
free survival in the same period was 95%. Furthermore, 
there was an improvement in early mortality that we 
believe  is  mostly  due  to  standardized  prophylactic 
platelet an fresh frozen plasma transfusion.
The  experience  of  IC-APL  have  shown  that 
networking  is  an  effective  tool  to  improve  medical 
assistance  and  infrastructure,  as  well  as  to  perform 
clinical  investigation  in  the  setting  of  developing 
countries. Although preliminary, IC-APL data suggest 
that  despite  minor  differences  in  the  laboratorial 
differences  exist,  the  clinical  outcome  of  APL  is 
similar once the early mortality is reduced by prompt 
diagnosis and effective supportive measures.
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